Lymphadenopathy-associated virus antibodies and T cells in hemophiliacs treated with cryoprecipitate or concentrate. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Lymphadenopathy-associated virus antibodies and T cells in hemophiliacs treated with cryoprecipitate or concentrate.

Blood. 1985 Sep;66(3):718-20. Unique Identifier : AIDSLINE MED/85280861
Gjerset GF; McGrady G; Counts RB; Martin PJ; Jason J; Kennedy S; Evatt B; Hansen JA

Abstract: Evidence for exposure to lymphadenopathy-associated virus (LAV) was investigated in 48 patients with hemophilia, 15 of whom had been treated exclusively with single-donor cryoprecipitate. The prevalence of antibodies to LAV in all patients was 53% in 1983 and 63% in 1984, while in patients treated only with cryoprecipitate, the prevalence was 31% in 1983 and 40% in 1984. Patients treated with any concentrate had a seroprevalence of 65% in 1983 and 77% in 1984. Seropositive patients were more likely to have a significant reduction in the ratio of helper to suppressor T cells, absolute numbers of helper T cells, and T cell function in vitro. Seven of 18 patients who were seronegative in 1983 had seroconverted by 1984. The relative risk of seroconversion for patients using any concentrate since 1981 compared with those using cryoprecipitate only was 3.9 (P = .04). Nevertheless, the rate of conversion in the latter group was 18% per year.
Keywords: Acquired Immunodeficiency Syndrome/ETIOLOGY Adolescence Adult Antibodies, Viral/*ANALYSIS Christmas Disease/*IMMUNOLOGY/THERAPY Factor VIII/*ADVERSE EFFECTS Fibrinogen/*ADVERSE EFFECTS Hemophilia/COMPLICATIONS/*IMMUNOLOGY/THERAPY Human HTLV-BLV Viruses/*IMMUNOLOGY Lymphocyte Transformation Middle Age Support, U.S. Gov't, P.H.S. T-Lymphocytes/*CLASSIFICATION/IMMUNOLOGY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/etiologyadolescenceadultantibodies,viral/KWDanalysischristmasdisease/KWDimmunology/therapyfactorviii/KWDadverseeffectsfibrinogen/KWDadverseeffectshemophilia/complications/KWDimmunology/therapyhumanhtlv-blvviruses/KWDimmunologylymphocytetransformationmiddleagesupport,uKWDsKWDgov't,pKWDhKWDsKWDt-lymphocytes/KWDclassification/immunologyjournalarticle
851230
M85C0116

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .